Spravato® approved for treatment of depression

December 11, 2020

The nasal spray, Spravato® (esketamine), is covered when deemed medically necessary to treat beneficiaries with treatment-resistant depression and other US Food and Drug Administration (FDA)-approved indications, which are available in the FDA’s Risk Evaluation and Mitigation Strategy (REMS) program. Prior authorization is required.

See the TRICARE Policy Manual (TPM), Chapter 7, Section 3.8 for more information.